Navigation Links
FAU Receives Patent for Invention Which Induces and Restores Cardiac Muscle Function
Date:9/21/2007

lotls (salamanders), these researchers identified a major protein that was deficient in these axolotl hearts which prevented the organization of myofibrils (contractile machinery) and the ability to beat. Using these findings, Lemanski, Zhang and their colleagues were able to show that this mutant defect could be rescued by treatment with specific and unique RNA (ribonucleic acid) derived from the anterior endoderm (gut) of normal animal model embryos. They cloned the gene for this specific RNA, synthesizing a "bioactive" RNA that is capable of rescuing mutant hearts by promoting the development and differentiation of contractile cardiac muscle cells from non-contractile, pre-cardiac, non-muscle cells.

Lemanski termed this discovery as "myofibrillogenesis inducing RNA" or MIR. Additional studies have shown that humans have a similar, most likely identical, mechanism as the axolotls, for the formation of functional contracting heart muscle cells. It may also be possible to produce new functional cardiac muscle tissue in areas of human hearts that require these cells and tissues for restoration of normal function.

"The issuance of this patent marks a tremendous achievement for Drs. Lemanski and Zhang as well as FAU, especially at a time when the United States Patent and Trademark Office (USPTO) continues to implement a tougher examination process," said Stephen Nappi, director of technology transfer and assistant vice president for research at FAU. "To continue to build upon this momentum, we will aggressively seek to identify and recruit the right company to help us bring this important invention to patients with cardiovascular disease."

Taken into the clinical setting, a human version of this MIR may allow patients who have suffered from heart attacks and have impaired physical activities due to scar tissue in their hearts to have those scarred areas replaced with new cardiac muscle. This treatment would therefore enable them to return to pre-he
'/>"/>

SOURCE FLORIDA ATLANTIC UNIVERSITY
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
4. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
5. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
6. Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results
7. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
8. Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response
9. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
10. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
11. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from ... China,s orthopedic instrument industry has seen ... rising from 3.28 billion yuan in 2006 to 9.85 ...
(Date:1/15/2014)... 2014 AARP Foundation today announced it has established a ... the severe cold weather that has gripped much of the ... in need; so to support these emergency relief efforts AARP ... which could mean up to $500,000 in aid. The matching ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Through Joint Venture Between Bristol-Myers Squibb and ... Its Kind in HIV Treatment -, PRINCETON, N.J. ... Commission has granted marketing authorization for,ATRIPLA(R) (efavirenz 600 mg/emtricitabine ... commercialization in the,27 countries of the European Union, as ...
... novel combination of drugs was,able to completely eradicate ... for the effective treatment of patients with advanced,metastatic ... University,School of Medicine presented the results of a ... pulmonary metastases in female SCID,mice., Paclitaxel is ...
Cached Medicine Technology:European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 2European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 3European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 4European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 5European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 6European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 7European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 8European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection 9New Drug Combination is Able to Eradicate Breast Metastases in Mice 2
(Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... chronic inflammation in benign prostate tissue was associated ... association was found even in those with low ... published in Cancer Epidemiology, Biomarkers & Prevention ... Cancer Research. , An analysis of prostate tissue ... arm of the Prostate Cancer Prevention Trial (PCPT) ...
(Date:4/17/2014)... the first genetic variant specifically associated with the ... around 10-15 per cent of all breast cancer ... breast cancer sub-type, called invasive lobular carcinoma, gives ... this particular kind of breast cancer, which can ... today (Thursday) in the journal PloS Genetics ...
(Date:4/17/2014)... One of the most popular vaccine brands for ... doctors may be overlooking some cost factors when choosing ... more expensive option, according to a new study by ... to administer can be driven by numerous factors," says ... a professor of computer science and of mathematics at ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2
... MIAMI, Sept. 11 Bupa,s ... a leading international healthcare company --,announced today the launch ... a deprived community in Ecuador where many families survive ... employees from around the globe will,travel to Ecuador until ...
... , DETROIT, Sept. 11 Blue Cross ... interim policy to automatically cover the cost of administration of the ... and individual coverage during the 2009-2010 flu season--unless a group chooses ... The Blues also announced that it will enable larger ...
... , , , ... magazine has ranked SoftLight Development, Inc. (SLD) NO. 643 on ... nation,s fastest-growing private companies. The list represents the most comprehensive ... entrepreneurs. Consumer electronics maker Vizio, Internet giant GoDaddy, rental car ...
... Sept. 11 During its 2009 Annual Conference in Washington, DC from ... some of the most pressing issues facing private care registries in the ... Conference include: , , , ... The program will cover PCA,s actions in the effort to ...
... , , , ... TD, pass completion , , CHICAGO, Sept. 11 ... Bears quarterback Jay Cutler means rooting for kids with diabetes. , ... Association (ADA) announced today they,re teaming up to help send children with ...
... , , , ... after bed bugs were believed to be exterminated nationwide, the teeny, ... proportions. , , They,re being spotted in ... motels, but posh resorts and upscale chains. In a recent study ...
Cached Medicine News:Health News:Bupa Launches its 2009 International Charity Challenge to Help a Rural Community in Ecuador 2Health News:Blue Cross Blue Shield of Michigan and Blue Care Network Announce Interim Policy to Cover H1N1 Vaccine Administration for Fully-Insured Groups During 2009-2010 Flu Season 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 2Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 3Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 4Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 5Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 6Health News:SoftLight Development, Inc. Ranks No. 643 on the 2009 Inc. 5000 with Three-Year Sales Growth of 429.7% 7Health News:Private Care Association to Tackle Major Issues Impacting Home Care Industry 2Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 2Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 3Health News:Chicago Bears Quarterback Jay Cutler, Eli Lilly and Company and the American Diabetes Association Team Up to Fund Diabetes Camp Scholarships Through "Touchdowns for Diabetes" 4Health News:Rest Easy, the Safe, All-Natural Bed Bug Travel Spray 2
... unique combination of topography, auto-refraction and keratometer ... three devices. The compactness of this instrument ... perfect space and cost saving solution. ... examination time and easy handling makes working ...
... SP-3000 covers all needs regarding pachymetry in ... care., ,Compact design, colored touch-screen and "quick ... an "easy-to-use unit.,The wide measurement range from ... the possibility to measure very thin or ...
The PillCam™ ESO video capsule is specifically designed to view the inner lining of the Esophagus. The capsule is equipped with miniature cameras on both ends and is about the size of a multi-v...
... Wave combines three advanced technologies - ... easy-to-use refractive diagnostic workstation. Now, with ... refraction, corneal topography, optical path difference ... Wave allows you to evaluate your ...
Medicine Products: